Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Rebetol Approved for Combination Use with Sovaldi for Genotype 2 Chronic Hepatitis C Virus Infection: MSD
July 30, 2015
- Teijin Pharma Files Feburic for Hyperuricemia in Patients Undergoing Chemotherapy in Japan
July 30, 2015
- Delving into Securities Filings - 2: Drug Maker Employees Decrease 0.9% in 5 Years
July 30, 2015
- New AbbVie Japan Chief Says Generics Making Room for Innovation
July 29, 2015
- Kyowa Kirin Kicks Off Japan PIII Study on Benralizumab for COPD
July 29, 2015
- EMA Accepts Applications for Opdivo for Non-Squamous NSCLC and in Combination with Yervoy for Advanced Melanoma: BMS
July 29, 2015
- Chugai’s Sales Reps to Provide ADR Information on the Spot from Mid-2016
July 29, 2015
- MSD Applies for 9-Valent HPV Vaccine
July 29, 2015
- Ixazomib Granted Accelerated Assessment in EU: Takeda
July 29, 2015
- Takeda, DNDi Partner for Development of Visceral Leishmaniasis Treatment
July 29, 2015
- Carfilzomib Approved for Combination Use in US: Ono
July 29, 2015
- Delving into Securities Filings - 1: Average Salary of 25 Makers Up 4.9% in 5 Years, Generic Players Close in on Top-Tier Firms
July 29, 2015
- Eisai Files for Regulatory Approval of Perampanel in Japan
July 28, 2015
- Japan Drug Makers Should Consider Mergers, Other Deals to Survive: Chugai Chief
July 27, 2015
- Toho to Narrow Down Recommended Drug Makers, Will Need to Devise Specific Marketing Policy for Generics: Pres. Edahiro
July 27, 2015
- Fujifilm, Kyowa Kirin JV to Develop Avastin Biosimilar with AZ
July 27, 2015
- Kyowa Kirin Ups Earnings Outlook on Nesp, G-Lasta
July 27, 2015
- Sumitomo Dainippon, Kyoto Univ., Hitachi to Collaborate on Regenerative Medicine for Parkinson’s Disease Utilizing iPS Cells
July 27, 2015
- Chugai Revenues Up 8.2% on Cancer Drugs, Actemra
July 24, 2015
- Toho to Differentiate Itself through Customer Support Rather than Prices: Pres.
July 24, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…